PFSA
Profusa, Inc.0.1121
-0.0101-8.27%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
7.36MP/E (TTM)
-Basic EPS (TTM)
-0.71Dividend Yield
0%Recent Filings
8-K
Debt cut to $14M
Profusa slashed net debt to $14 million as of October 31 via recapitalization and fresh capital raises post its July merger with NorthView, boosting cash to $4 million. Manufacturing is primed for early 2026 Lumee Oxygen shipments, with European distributors covering 35% of population and new surgeon collaborations in place. Debt stays elevated. Forward-looking revenue targets: $0.5-2M in 2026.
10-Q
Q3 FY2025 results
Profusa posted Q3 FY2025 operating loss of $21.7M, up sharply y/y from $1.1M (derived), driven by $15.1M Business Combination transaction costs that spiked G&A to $21.0M; net loss hit $22.2M vs $2.5M y/y, widened by $1.4M ELOC financing costs yet narrowed by $0.9M gain on warrant fair value. Merger closed July 11, 2025, converting preferred stock and $46.9M debt to common shares, slashing liabilities from $57.1M to $38.2M while boosting cash to $3.0M; $14.4M related-party loans payable (fair value) loom long-term, with $3.5M ELOC drawn. Operating cash burn tallied $11.1M YTD. Nasdaq compliance hangs by a thread.
8-K
Nasdaq MVPHS deficiency notice
Profusa received a Nasdaq notice on October 27, 2025, for failing to maintain a $15 million Market Value of Publicly Held Shares over 30 consecutive business days ending October 24. Trading continues uninterrupted under PFSA with 180 days until April 27, 2026, to hit $15 million for 10 straight days. Company plans to monitor and pursue options. Delisting looms if unmet.
8-K
Profusa maps $250M revenue path
Profusa outlined its revenue path via press release, targeting Lumee Oxygen launch in EU early 2Q 2026 after CE Mark in late 1Q 2026, with $0.5-2M potential revenue that year at €600-€800 per procedure and €30-40K equipment per center. US entry and EU Glucose follow in 2027, scaling to $200-250M by 2030. Distribution covers 35% of EU population. Forward-looking estimates carry execution risks.
8-K
Profusa updates investor deck
Profusa published its October 2025 investor presentation under Regulation FD, outlining Lumee Oxygen platform launch for critical limb ischemia monitoring—EU 1Q2026, US 1H2027—with projected 2026 revenue of $0.5-2M scaling to $200-250M by 2030 alongside glucose pipeline. Backed by $22M PIPE ($12M drawn), $100M ELOC ($5M drawn), and 85 patents, it targets $10.5B+ oxygen TAM. Cash runway covers 16 months.
AMIX
Autonomix Medical, Inc.
0.63-0.03
FZMD
Fuse Medical, Inc.
0.07+0.00
IRME
IR-Med Inc.
0.02-0.01
MODD
Modular Medical, Inc.
0.34-0.03
NUMD
Nu-Med Plus Inc.
0.02-0.01
PMI
Picard Medical, Inc.
2.30-0.13
PROF
Profound Medical Corp.
7.55-0.14
SENS
Senseonics Holdings, Inc.
6.62-0.17
SERA
Sera Prognostics, Inc.
3.56+0.18
SMLR
Semler Scientific, Inc.
17.40+1.37